Real World Experience With Heart Failure Management System (HFMS)- An Initial Single-center Experience

Akanksha Agrawal,Melissa Buckner,Jason Feliberti,Joel Fernandez,Debbie Rinde-Hoffman
DOI: https://doi.org/10.1016/j.cardfail.2023.10.249
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction Nearly 1 in 4 heart failure (HF) patients are readmitted within 30 days of discharge and approximately half are readmitted within 6 months. The annual expenditure on patients with heart failure is approximately $30.7 billion, which is expected to rise to $53 billion by 2030. Multiple techniques are implemented at various levels with the aim to decrease the readmission rate. Heart Failure Management System (HFMS) is a non-invasive device, that uses radiofrequency technology for early detection of changes in pulmonary fluid levels, an increase of which is an early indicator of HF decompensation. Methods This was a single center pilot experience of patients diagnosed with heart failure, who were given HFMS prescription with the aim to reduce the 30-day HF readmission rate. Within 24-48 hours of discharge from their HF admission, the patch was delivered to the home with instructions for use. The national Independent Diagnostic Testing Facility (IDTF) helped in facilitating proper placement, connection and baselining. “Alerts” were defined as abnormal thoracic fluid index (TFI) (3 standard deviation above baseline for 3 consecutive days), ventricular tachycardia (VT) >150 for 30 seconds or asystole for 8 seconds. Based upon a predetermined alert protocol, specifically the hypervolemia protocol, the clinical team received an alert via a phone call and the report was also electronically delivered to the office. A weekly report was also received with and without alerts from the IDTF. Per hypervolemia protocol, adjustments were made to the diuretic and other medications as indicated. If an outpatient or emergency visit was deemed appropriate by the physician, the same was advised. Results Between February 2022 and July 2022, a total of 32 patients received the prescription for HFMS during their heart failure admission. All patients were NYHA Class III or IV and HF Stage C or D. Amongst 32 patients, 23 (72%) performed the initial baseline and were compliant with wearing the device, and 9 (28%) did not perform initial baseline. Amongst the 23 patients, one was electively readmitted with organ offer for heart transplantation. One patient out of 23 (4.3%) had 2 alerts for which telephonic adjustment of diuretic was made followed by outpatient appointment. Amongst the 9 patients who did not perform the initial baseline assessment, 5 (55%) were readmitted to the hospital within 30 days. The average 30-day readmission rate for HF at our center without HFMS was 22%, similar to national average. Conclusion About a quarter of patients who were prescribed the HFMS did not comply and did not perform baseline metrics. Greater than 50% of the patients who never baselined were readmitted within 30 days. In our small study, one readmission was prevented by using the HFMS device. Large scale data and follow up is required around this novel technology, however compliance seems to be the primary hurdle.
cardiac & cardiovascular systems
What problem does this paper attempt to address?